Multiple Myeloma Articles | Page 2

Studies Stopped for Daratumumab/Checkpoint Inhibitor Combos in NSCLC, Myeloma
Two separate early-phase clinical trials exploring daratumumab in combination with either a PD-1 inhibitor for multiple myeloma or a PD-L1 inhibitor for non–small cell lung cancer were terminated following a planned interim analysis.
Selinexor Tested in Combination With Standard Therapy in Multiple Myeloma
The BOSTON trial is randomizing patients with relapsed/refractory multiple myeloma to a triplet combination of selinexor (KPT-330), bortezomib (Velcade), and dexamethasone versus a combination of bortezomib and dexamethasone.
A. Keith Stewart, MB, ChB, and a panel of hematology experts review data concerning emerging frontline strategies for multiple myeloma that were presented at the 2017 ASH Annual Meeting.
In updated guidelines exploring the role of bone-modifying agents, ASCO has recommended expanding the use of bisphosphonates to include all patients being treated for active multiple myeloma. 
Jeffrey Wolf, MD, emphasizes the importance of identifying risk when diagnosing patients with multiple myeloma.
Expert Summarizes Strides in Relapsed Myeloma, Says More to Come
Peter Voorhees, MD, discusses treatments for patients with early relapsed multiple myeloma and previews future research efforts.
FDA Approves Frontline Daratumumab/VMP Combo for Multiple Myeloma
The FDA has approved daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
 
Usmani Discusses MRD and Other Myeloma Developments
Saad Z. Usmani, MD, discusses the clinical applications of minimal residual disease and managing patients with relapsed/refractory multiple myeloma.
Selinexor Again Shows Promise in Heavily Pretreated Myeloma
Selinexor induced an overall response rate of 25.4% in patients with penta-refractory multiple myeloma, according to top-line results from part 2 of the phase IIb STORM trial. 
European Panel Backs Carfilzomib Label Update in Myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended adding final overall survival data from the phase III ASPIRE trial to the  label for carfilzomib for the treatment of patients with relapsed/refractory multiple myeloma. 
 
Publication Bottom Border
Border Publication
x